

**Funded Expressions of Interest  
1 January 2010 to 30 June 2011**

Associate Professor David **Anderson**, Burnet Institute. 'Quantitative determination of CD4+ T-cells at point of care'.

Associate Professor Michael **Beard**, University of Adelaide. 'Development of Laboratory-Based Platforms To Manage Patients Who Develop Antiviral Drug-Resistance To The Specifically Targeted Antiviral Therapies for Chronic Hepatitis C (STAT-C)'.

Dr. Mandvi **Bharadwaj**, University of Melbourne. 'Novel measures for induction of effective Hepatitis C Virus (HCV)-specific T-cell immunity'.

Dr. Rowena **Bull**, University of New South Wales. 'Viral complexity and cross-reactive immunity as predictors of clearance in HCV infection'.

Dr. Robert J. **Center**, University of Melbourne. 'Assessing the immunogenicity of a novel brain-derived HIV envelope protein'.

Professor Tony **Cunningham**, Westmead Millennium Institute for Medical Research. 'Can HIV lipopeptide immunogens induce Th17 Responses?'

Dr. Russell **Diefenbach**, Westmead Millennium Institute for Medical Research. 'Development of inhibitors of dynein-dependent transport of HIV: a new antiviral strategy'.

Dr. Julian **Elliott**, Burnet Institute. 'Investigation of biological mechanisms linking abacavir use and cardiovascular disease using mRNA profiling'.

Professor James **Flexman**, Royal Perth Hospital and University of Western Australia. 'Development of Novel Therapeutics for Treatment of Hepatitis C Infection'.

Associate Professor Paul **Gorry**, Burnet Institute. 'In vitro assay for HIV resistance to the CCR5 inhibitor Maraviroc'.

Dr. Gholamreza **Haqshenas**, Monash University. 'High throughput screening assays for the identification of potential inhibitors of hepatitis C virus p7'.

Associate Professor David **Harrich**, Queensland University of Technology. 'Null-Basic: A Novel HIV-1 Inhibitor'.

Dr. Karla **Helbig**, University of Adelaide. 'Imatinib Inhibition of HCV Replication'.

Dr. Marcel **Hijnen**, Burnet Institute. 'High throughput screening and functional evaluation of HIV assembly/maturation inhibitors'.

Professor Stephen **Kent**, University of Melbourne. 'Adjuvanted 2nd-generation nanoengineered capsule vaccines for HIV'.

Associate Professor Hans **Netter**, Monash University. 'Recombinant virus-like particles for the delivery of HIV-1 neutralising epitopes arrayed at high density'.

Dr. Raelene **Pickering**, Monash University. 'Can IL-28 / IL-29 production be used as a prognostic marker for Hepatitis C (HCV) outcome?'

Associate Professor Damian **Purcell**, University of Melbourne. 'Neutralising antibody to HIV-1 ENV from hyperimmune bovine colostrum as a mucosal microbicide'.

Dr. Nitin **Saksena**, Westmead Millennium Institute for Medical Research and University of Sydney. 'Determination of the diagnostic value of gag gene mutation at position 16 in HIV-1 for predicting below detectable levels of HIV during HAART'.

Dr. Jasminka **Sterjovski**, Burnet Institute. 'Rapid HIV-1 tropism testing using novel, soluble mimics of the HIV-1 coreceptors CCR5 and CXCR4'.

Dr. Stuart **Turville**, University of Sydney. 'Inhibition of Dynamin II (DynII) as a HIV therapeutic and microbicide strategy'.

Dr. Clare **Westhorpe**, Burnet Institute. 'Markers of monocyte activation AS correlates of CardioVascular Disease in HIV patients'.

Associate Professor Peter **White**, University of New South Wales. 'Identification of Chemical Compounds for Hepatitis C Virus Polymerase Inhibition'.

Dr. Charani **Ranasinghe**, The Australian National University. 'Use of Cytokine Trap Technology to Augment T cell Avidity Against HIV Vaccine Antigens'.

Associate Professor Joseph **Torresi**, University of Melbourne. 'Genetic modification of HCV VLP vaccines to enhance humoral immunogenicity'.